i3 BioMedical

i3 BioMedical was a Canadian healthcare products company focused on antimicrobial and antiviral protective medical products, particularly masks and related consumables incorporating its TrioMed Active surface-coating technology. The company marketed infection-control products designed to deactivate pathogens on contact or within minutes, with public validation efforts centered on SARS-CoV-2 testing performed by University of Toronto researchers. Its business appears to have been product- and technology-driven rather than a therapeutic drug-development model, placing it closer to the medical device and infection-prevention segment than to traditional biotech or pharma. Corporate records indicate that I3 BioMedical Inc. was incorporated in 2014 in Quebec, Canada and was amalgamated into T3 Medcell Corporation on January 1, 2026.